ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

Transforming Pharmaceutical Innovation Through Artificial Intelligence: Revolutionizing Drug Discovery

Ragni Patel[1]; Dip Patel[2]; Divya Patel[3]; Dr. Manan Sharma[4]; Dr. Anjali Gupta[5]; Dr. Akshat Parashar[6]

[1,2,3]Pharm. D Students; [4,5,6]Assistant Professor

[1,2,3]Saraswati Institute of Pharmaceutical Science, Dhanap, Gandhinagar
[4]SIRT-Pharmacy, SAGE University, Bhopal (MP)
[5]Department Of Pharmacy, Madhav University, Aburoad, Rajasthan
[6]Institute of Pharmacy, Madhav University, Aburoad, Rajasthan

Publication Date: 2026/04/16

Abstract: Drug discovery still has a very high failure rate above 90% in clinical trials, takes 10 to 15 years to develop, and costs US$2.6 billion on average for each drug that finally reaches the market [1]. These inefficiencies and the long time required for drug discovery processes present one of the major challenges to the provision of the required medicines. However, the development of AI is transforming the drug discovery model into a faster, more precise and cheaper process. AI is applied throughout the drug discovery process, screening the literature and high-throughput omics data (such as genomics, transcriptomics, proteomics and metabolomics), playing a key role in the accurate identification of novel disease targets through machine learning and natural language processing [2][5]. The use of AI-based molecular docking and predictive models has allowed virtual screening to change from a time-consuming process to a faster high-throughput drug discovery process [6,17]. AI-driven lead optimization generates and optimizes lead compounds using generative models such as GANs and reinforcement learning to provide the best combination of pharmacological and ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties [19,22,23]. In addition to narrowing down patients for preclinical and clinical trials, Al can predict whether the trial will succeed or fail, and monitor its progress [7]. By rapidly identifying adverse drug reactions from a variety of real-world data sources, Al systems significantly boost post-marketing surveillance [7]. Even though there are still issues with data quality, model interpretability, and the changing regulatory environment, Al's obvious advantages—such as significant time and cost savings in research, enhanced data integration, and the development of personalized medicine—highlight its crucial importance [4].Future drug research is anticipated to incorporate fully autonomous Al platforms and quantum computing, increasing treatment options, particularly for targets that were previously deemed "undruggable." Al is a significant change that will enable patients to receive life-saving drugs with previously unheard-of efficiency and speed. He is more than just a small improvement.

Keywords: *Artificial Intelligence, Drug Discovery, Machine Learning, Clinical Trials.*

How to Cite: Ragni Patel; Dip Patel; Divya Patel; Dr. Manan Sharma; Dr. Anjali Gupta; Dr. Akshat Parashar (2026) Transforming Pharmaceutical Innovation Through Artificial Intelligence: Revolutionizing Drug Discovery.
International Journal of Innovative Science and Research Technology, 11(4), 760-768.
https://doi.org/10.38124/ijisrt/26apr430

I. INTRODUCTION

The process of discovering new drugs is difficult and resource-intensive; it usually takes 10 to 15 years, and each successful drug costs more than $2.6 billion [1]. Receiving treatments becomes more difficult as a result, particularly for severe or uncommon conditions. Target identification and validation, lead optimization, preclinical testing, lead discovery (typically via high-throughput screening), and multi-phase clinical trials are the sequential stages of the typical pipeline [1]. Despite these efforts, the process is extremely wasteful because over 90% of candidates fail clinical trials [1].

A potential substitute is provided by recent developments in AI [2]. These days, using artificial intelligence (AI) tools to predict safety and efficacy profiles, synthesize molecules, and find new targets can save time and

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

money [2, 3]. According to a 2023 Nature Reviews Drug Discovery study, out of 42 AI-discovered compounds in Phase I trials, 21 were successful, and several are still proceeding through further stages, indicating AI's increasing influence on drug development [37].



Fig 1 Progress and Outcomes of AI-Discovered Molecules in Clinical Trials, Including Breakdown by Phase and Type (Source: Nature Reviews Drug Discovery, 2023).

II. IMPORTANCE

A vital part of modern healthcare is drug discovery, which is basically the lifelong process of developing new medications to fight the various diseases that affect people all over the world [1]. It is very important because it deals with some very important issues. Above all, it is essential for filling in the gaps in situations where there are no effective treatments. Despite all of our progress, there are still many diseases for which there are no effective treatments, including diabetes, Alzheimer's, advanced cancers, and newly emerging infectious diseases [1]. Millions of people with chronic illnesses continue to have hope thanks to the development of new drugs, which allow them to live longer, better lives and sometimes even fully recover from them [1]. If drug discovery research stopped, patients would have few options, which would lead to a rise in illness and mortality. Second, this field is essential for addressing health hazards that are always changing. Examples of microorganisms that are continuously changing and developing resistance to contemporary drugs are bacteria and viruses. Antibiotic-resistant microorganisms are important because they have the potential to make common illnesses incurable. Drug discovery produces new antibiotics, antivirals, and vaccines—tools we really need to stay ahead of these changing threats and prevent serious health emergencies like pandemics [1]. The quick development of COVID-19 vaccines and treatments during the most recent outbreak highlights the significance of this goal. Third, the economy is stimulated and innovation is encouraged by drug discovery. The pharmaceutical industry spends billions on research, creates many highly skilled jobs, and advances science and technology. When a new medication enters the market and brings in a substantial amount of money, it creates a cycle of ongoing innovation that is often reinvested in further research. In addition to the industry, the tech, healthcare, and research sectors also gain from this economic boost. Furthermore, developing new drugs enhances patient outcomes and boosts the effectiveness of healthcare as a whole. Effective medications can shorten hospital stays, expedite recovery, and lessen the need for invasive procedures—all of which lower healthcare costs. For

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

example, antiretroviral therapies for HIV transformed the once fatal disease into a chronic, treatable condition, which lessened the strain on healthcare systems. Similar to this, new cancer treatments are enhancing lives and public health by achieving long-term remission rather than just managing symptoms. Last but not least, drug discovery broadens our understanding of science. When researchers find new targets, comprehend how diseases work, or develop compounds that interact with our bodies, they are advancing our overall understanding of human biology and disease processes. Every medication that works validates a scientific theory and offers valuable information that encourages further research and develops new treatments. Because of this never-ending quest for knowledge that keeps pushing the limits of bioengineering and medicine, drug discovery is a crucial part of human progress [1].

Statistics gathered over time show that between 2015 and 2023, there was a significant increase in the number of drug candidates found using AI [37]. By 2023, there will be 67 molecules undergoing clinical trials, compared to just one in 2015 [37]. These trials are gradually increasing throughout all phases, as shown in Graph (a), with Phase I experiencing the biggest increase in 2023, reaching 45 molecules. Interestingly, two of these compounds made it to Phase III, and one of them even went on sale that year [37]. Graph (b) then breaks down the types of molecules we are talking about, and it turns out that the trend in 2023 is being driven by tiny molecules [22] and AI-designed targets [24]. Repurposed drugs, vaccines, and antibodies are behind them. All of this simply shows how much AI is speeding up the entire process of finding new drugs [37].



Fig 2 Year-Wise Increase and Classification of AI-Discovered Molecules in Clinical Trials by Type and Phase (Source: Nature Reviews Drug Discovery, 2023).

III. CONVENTIONAL METHODS

Chemical synthesis, biological testing, and testing on living organisms are the main components of the traditional approach to discovering new drugs, which is based on a series of processes that usually involve a significant amount of time and effort, as well as a significant amount of experimentation and observation [1].

The first crucial step in deciding which part of the condition we should concentrate on is target identification and validation. To understand the molecular elements that underlie a disease, deep biological research is usually the first step. This includes cell behaviour analysis, protein and enzyme analysis, and genetic research. Scientists experiment with a number of techniques, including gene knockdown, protein overproduction, and the use of small chemicals, to see if changing a target truly affects the disease. This process may take some time because it is hypothesis-driven and

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

complex—diseases often involve a large number of biological pathways and data. An example would be determining whether a new GPCR (type of receptor) is likely to be a good target may take many years of cloning, expression testing, and binding analysis. Once it is confirmed that the GPCR can be successfully used as a target, the next step is to find the first compounds, or "hits," to bind to those targets. High-throughput screening (HTS) has historically been a technique used to do this [6,17,19]. HTS requires testing significant chemical libraries of hundreds to thousands, or even millions, of compounds against those targets using small assay plates with automated robots. The goal of HTS is to find out which compounds attach to the target, or change its activity, for example: by activating a receptor; or by inhibiting an enzyme [1]. However, while HTS allows for large numbers of compounds to be tested quickly, it can also be quite costly, require a large number of reagents, and frequently produce "false-positive" results or hits for drugs that will not be useful. You need to conduct further tests to confirm any promising finding (i.e., candidate for drug development). There are many different older methods of drug discovery compared to HTS. These methods include virtual screening where you use a computer-generated model of a protein to determine whether a molecule is likely to bind and fragment-based approaches that screen small molecules [18]. After you have some confirmed "hits", lead optimization will follow [1].

This process allows many compounds to be tested quickly (high-throughput screening), but it is a great deal of money, uses a lot of reagents, and often results in obtaining false alarms, or false positives, for drugs that may not be beneficial. Therefore, any compound that shows promise should be thoroughly confirmed via additional testing. In addition to high-throughput screening, older methods have evolved; virtual screening, through computational modelling, has continuously improved with education and advancements in technology, and fragment-based screening has provided an opportunity to evaluate small molecule libraries [18]. Once you find confirmed hits, the next step in the pharmaceutical development process is to carry out lead optimization [1].

Medicinal chemists create many new versions of these compounds in an iterative process, changing their structures to make them more potent, targeted, and drug-suitable. They accomplish this through structure-activity relationship research, which involves changing small parts of the molecule and monitoring the impact on binding and activity. They concentrate on features such the drug's efficacy, solubility, stability in the body, selectivity (to avoid side effects), and ease of intracellular transport to the target. By enhancing absorption, distribution, metabolism, excretion, and reducing toxicity, the goal is to guarantee that the medication can carry out its role in a safe and effective manner [7,22,23,24]. Chemists' skills and knowledge are crucial in this process, which entails multiple iterations of synthesis and testing. To make the substance easier to swallow, for example, it might be necessary to add specific groups or change its polarity, which could require additional research and testing stages [1].

After a lead candidate has been optimized, preclinical testing comes next. This requires a great deal of laboratory effort and animal testing to determine whether the drug is safe and has some potential before starting human trials. Examples of laboratory-based in vitro experiments include cell toxicity evaluations, enzyme blocking tests, and receptor binding investigations. The drug's behaviour in the body (pharmacokinetics), its effects on the body (pharmacodynamics), and its safety in both short-term and long-term circumstances are then investigated through animal testing utilizing various models, such as mice, rabbits, or even primates. As an illustration, we would test a new cancer drug to see how well it eliminates tumours in mice without causing too many negative effects. For example, while testing a new cancer medication, we would look at how well it shrinks tumours in mice with little side effects.

In order to get permission to test the drug on humans, the outcomes of these strictly controlled and morally acceptable animal experiments are essential. But bear in mind that animals and people are not exactly alike, thus the reaction could occasionally differ. The drug next proceeds to clinical trials, which are often the most costly and time-consuming [1].

These experiments are divided into three main phases: Phase I: A limited number of healthy volunteers, between 20 and 100, test the drug to ascertain its safety, figure out the right dosage, and identify common side effects. Phase II: More people with the condition the drug is meant to treat (about 100–300) are tested. This phase assesses the medication's efficacy, assesses safety further, and helps with dosage modification. Phase III: Extensive studies involving hundreds or even thousands of patients with the goal of confirming the drug's effectiveness, closely monitoring side effects, and comparing it with existing treatments. These may occur across multiple centres and must provide strong evidence for approval. One of the biggest challenges in traditional clinical research is recruiting and keeping enough volunteers, which can lead to delays and higher costs. The method is also rather difficult because collecting and analysing side effect data requires a substantial amount of physical labour.

After clinical trials are successfully completed, a comprehensive data dossier is prepared for regulatory submission to agencies like the FDA or EMA. All preclinical and clinical data must be meticulously gathered and examined in order to demonstrate the medication's efficacy and safety. As part of post-marketing monitoring, the drug's effectiveness in the general population is tracked after approval with the goal of finding rare or persistent side effects that would not have been apparent during clinical trials. This often relies on spontaneous reporting systems and passive data collection.

Even while it has been successful in creating a number of life-saving medications, the traditional drug development pipeline is slow, costly, and prone to high failure rates due to its sequential, empirical, and often time-consuming nature. Each step of the process has a unique set of obstacles, making

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

it a challenging enterprise prepared for technological transformation [1].

IV. APPLICATIONS OF AI IN THE FIELD

AI is radically changing the process of finding new drugs. It's making the process of discovering, creating, and refining new drugs much faster, smarter, and more cost-effective. AI's capacity to handle massive, complicated data sets, automate difficult tasks, and generate somewhat accurate predictions simplifies the entire process [2,4]. Finding the target, it is critical to choose the right biological target early on. In the past, this required a great deal of time-consuming laboratory research and was often limited by the available genetic data, which occasionally led to several false starts [2].

These days, AI systems employ many omics data types, including transcriptomics, proteomics, and genomics, to accurately identify genes or proteins associated with disease. For example, machine learning algorithms trained on different disease data can identify novel biomarkers or targets that scientists would miss. Additionally, advanced language processing algorithms, like more current versions of IBM Watson, can analyse millions of academic papers, patents, and clinical studies to find hidden correlations and suggest potential therapeutic targets [5].

In particular, for complex diseases like cancer or neurological disorders that are challenging to treat with conventional methods, this technique greatly shortens research time and opens up several new prospects. Identification of Hits and Virtual Screening The next step is to identify compounds known as hits that can stick to a target and change its activity. AI in virtual screening has totally superseded the prior, time-consuming, high-throughput screening strategy that may take months to find many good candidates [6].

These days, AI-powered methods use smart molecular docking simulations and predictive models to quickly assess millions of molecules on a computer [6,17,18]. Because we can evaluate potential drugs in a matter of days rather than months, this saves a significant amount of time and money [6]. Two techniques that capture even the tiniest atomic-level details of chemical interactions are convolutional neural networks and graph neural networks [17]. Platforms like AtomNet and DeepChem [30] employ deep learning to predict a compound's binding strength, potential toxicity, and eligibility as a treatment candidate with surprising accuracy [17,20].

This significantly speeds up the procedure and lower the amount of substances that need to be physically tested in a lab, which is highly advantageous for resources [6]. For instance, Atomwise uses deep learning with its AtomNet platform to estimate binding strength based on three-dimensional molecule architectures, yielding faster and more accurate results than traditional methods [29].

V. LEAD OPTIMIZATION

It is essential to improve a promising molecule's absorption, efficacy, and safety in order to turn it into a viable drug candidate. AI approaches are quite good at predicting these important ADMET traits early on, saving time and money on future failures [6,32]. These days, completely new medication formulations are being developed from the ground up utilizing techniques like reinforcement learning and Generative Adversarial Networks (GANs), improving their properties along the way [19,22,23]. By learning from large databases of known compounds, they can suggest new variants that might be more potent, more soluble, or less hazardous. They often delve into chemical possibilities that even seasoned scientists could miss. Additionally, by using automated technologies like AiZynthFinder, which boost efficiency, scientists may be able to figure out how to actually synthesis these novel molecules in the lab [10,31]. Even platforms like Chemistry42 in Insilico Medicine use these advanced models to develop new, drug-like molecules that are customized to meet specific needs [27].

VI. PRECLINICAL AND CLINICAL TESTING

AI is revolutionizing the design and management of preclinical and clinical trials [7]. AI can help preclinical researchers choose the best animal models by analysing their genetic composition or expected pharmacological effects, making it easier to visualize possible human consequences. Artificial intelligence (AI) enhances the process of identifying eligible volunteers for clinical trials by looking through enormous amounts of genetic data, electronic health records, and real-world information to find people with the right medical symptoms or genetic markers. Additionally, machine learning algorithms can monitor side effects, make sure patients adhere to their treatment plans, and assess the trial's progress in real time—all of which make the process safer and more successful overall. We can make smarter judgments faster and save time and money on studies that are likely to fail thanks to AI's predictive capacity, which also helps uncover early indicators of a trial's likelihood of success or failure [7]. For example, BenevolentAI used its AI-powered knowledge network to locate drugs like baricitinib that may be effective against COVID-19, speeding up efforts to find new uses for existing pharmaceuticals [29]. Recursion Pharmaceuticals, another company, uses AI and high-speed cell imaging to quickly discover medications that can reverse disease symptoms, especially for rare genetic illnesses [26].

VII. REGULATORY SUBMISSIONS AND POST-MARKETING SURVEILLANCE

Regulatory science is now using AI to assist develop comprehensive data packages that more successfully meet stringent regulatory requirements from agencies such as the FDA and EMA [7,33,34]. By collecting, validating, and even modelling pharmacokinetic and toxicological data for regulatory evaluation, AI models can assist guarantee data integrity and consistency. AI systems also significantly enhance post-marketing surveillance, which is a crucial part of pharmacovigilance. By mining vast volumes of patient

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

feedback, social media data, and electronic medical records, these systems can swiftly uncover adverse drug responses (ADRs) that might not have been observed during clinical trials. AI-powered pharmacovigilance systems have the potential to save lives by enabling quicker safety interventions and improving overall pharmaceutical safety profiles by notifying authorities significantly more swiftly than manual techniques [7].

VIII. KEY AI TECHNOLOGIES IN DRUG DISCOVERY

➢ *The Various Applications of AI in Drug Discovery are Supported by Several Basic Technologies:*

Machine learning (ML), a crucial part of artificial intelligence, enables systems to identify patterns in data and make predictions without explicit programming [2,36]. Machine learning methods predict compound bioactivity, pharmacokinetic properties, and potential toxicity in drug development based on chemical structures and biological data [2,32,38]. Supervised learning techniques like random forests and support vector machines classify compounds as active or inactive, while unsupervised learning techniques like clustering and dimensionality reduction uncover hidden structures in chemical and biological datasets, narrowing the chemical space to promising candidates [2,36].

- Deep Learning (DL): A subfield of machine learning (ML), DL uses multi-layered neural networks to alter pattern recognition [20]. CNNs and RNNs are used to evaluate molecular graphs, protein sequences, and three-dimensional complex structures [17,20,24]. Because DL models automatically extract complex features from raw data, compound-target binding affinities, ADMET profiles, and drug-likeness can be predicted with higher accuracy. Platforms like DeepChem provide open-source resources for DL in medicinal chemistry [30].

- Natural language processing (NLP): NLP, or the ability of machines to understand and evaluate human language, is essential for making inferences from vast amounts of biomedical literature, clinical trial reports, and patent databases [5]. Natural language processing (NLP) AI algorithms can identify drug-target correlations, adverse events, and opportunities for drug repurposing by reviewing millions of papers [21]. By using named entity identification and relationship extraction tools to build structured databases from unstructured scientific publications, researchers can swiftly make evidence-based decisions [5].
- Reinforcement Learning (RL): RL models use trial-and-error encounters to learn a set of decisions [23]. RL is used in drug discovery for de novo drug design, producing novel compounds with desired biological and chemical properties by rewarding the model for producing molecules that meet specific parameters, such as high binding affinity or low toxicity [9,23]. This could lead to entirely new chemical scaffolds that aren't found in traditional libraries [23]. In-silico Medicine has successfully used RL to develop novel inhibitors [9].

- Generative models (like GANs and VAEs) create new chemical entities by learning from existing molecules [19,22]. After being trained on large databases of drug-like molecules, they can generate compounds with desirable physicochemical and biological features [25]. GANs are particularly adept at producing distinctive and realistic molecules that wander beyond of traditional chemical space because to their generator-discriminator architecture. They can also be combined with RL for fine-tuning [19].

- Protein Structure and AlphaFold Prediction: DeepMind's AlphaFold is a revolutionary AI tool that accurately predicts the three-dimensional structure of proteins using amino acid sequences [8]. Protein structure prediction has long been a bottleneck because rational drug design necessitates a grasp of a target's three-dimensional conformation. AlphaFold's unparalleled accuracy (as demonstrated in CASP14) and its open-source collection of over 200 million protein structures, which allows for more precise virtual screening and binding site identification, are significantly accelerating target-based drug design efforts worldwide. Researchers are already using AlphaFold data to investigate new treatments for diseases like malaria and tuberculosis, and pharmaceutical companies are integrating these predictions into their early-stage operations [8].

These different AI tools significantly boost drug research productivity and efficiency at every stage when utilized responsibly [2].

Table 1 Advantages and Disadvantages of AI in the Field

Advantages of AI in the Field	Disadvantages of AI in the Field
Speed and Cost Reduction: Al significantly reduces the time and cost to bring new drugs to market, performing tasks in days that traditionally took months or years. This accelerates early-stage research and R&D productivity by prioritizing promising compounds and avoiding costly late-stage failures [4, 12, 20].	Data Quality and Availability: Al models are highly dependent on the quality, quantity, and relevance of their training data. Much biomedical data is fragmented, noisy, incomplete, or siloed, hindering seamless integration and leading to suboptimal or inaccurate predictions [4, 25].
Handling Complex, Multi-modal Datasets: Al can process and synthesize vast and diverse datasets (e.g., multi-omics, EHRS, chemical libraries, scientific publications), uncovering intricate patterns and correlations invisible to human analysts. This leads to more accurate target identification, biomarker discovery, and higher confidence in lead selection [4].	Bias in Training Data: Incomplete or non-diverse datasets (e.g., predominantly from specific ethnic groups) can lead to Al algorithms overlooking crucial drug-target relationships or adverse effects relevant to underrepresented populations, resulting in less effective or harmful drugs for certain patient groups [4].

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

Advancing Personalized Medicine: By analysing genomic, proteomic, and phenotypic data, Al helps tailor drug development to specific biological profiles, leading to more effective and safer drugs for particular patient populations [4].	Interpretability and Explainability ("Black Box" Problem): Many advanced deep learning models function as "black boxes," providing predictions without insight into the rationale. This lack of transparency hinders trust, makes troubleshooting difficult, and prevents mechanistic understanding [4].
Enhancing Drug Repurposing Efforts Al algorithms can rapidly analyse existing drug properties and clinical data to identify potential new indications for approved drugs. For example, Al identified baricitinib and remdesivir as potential COVID-19 therapies [4, 13, 21, 28].	Regulatory Uncertainty: Regulatory bodies are still developing comprehensive frameworks for evaluating Al-based evidence and predictions. This evolving landscape can create ambiguity and potentially delay approval for Al-discovered or Al-optimized drugs [4, 33, 34].
Reducing Late-Stag Attrition Rates: Predictive Al models forecast ADMET properties, toxicity, and preliminary efficacy earlier, de-risking candidates and preventing significant investments in drugs likely to fail in expensive clinical trials [4, 23].	Resistance to Adoption: Some traditional researchers and clinicians may be spectacle due to a lack of understanding of Al methodologies, perceived threats to established practices, or insufficient training. Bridging this gap requires education, clear value demonstration, and user-friendly interfaces [4, 33, 34]
Increasing Accessibility to High-Quality Drug Discovery: Al democratizes advanced research capabilities, enabling smaller biotech firms and academic laboratories to conduct sophisticated drug discovery, fostering innovation and competition globally [4].	Validation in Real-World Settings: Al models performing well in silico may not translate to comparable success in wet-lab experiments or clinical the complexity of environments due to biological systems. This necessitates rigorous benchmarking, prospective trials, and interdisciplinary collaboration [4].

IX. FUTURE SCOPE

The pharmaceutical sector may undergo significant change as AI in drug development is predicted to increase exponentially and become more thoroughly integrated in the future. Future research should focus on developing fully autonomous AI-driven drug discovery systems. These integrated technologies will seamlessly link target selection, de novo molecular design, synthesis planning, and preclinical testing through closed-loop feedback mechanisms, significantly reducing human intervention and accelerating the pipeline [6,15,16].

Advances in robotics and laboratory automation have made it possible to produce and test AI-designed compounds autonomously, leading to self-improving discovery cycles [6,16].

Another important area is the development of AI models that are simpler to comprehend and describe (XAI). As AI systems get more advanced, it will be crucial to comprehend why they produce certain substances or make specific predictions in order to guide human researchers and obtain regulatory permission. Future XAI research will focus on developing methods that provide more transparent insights into AI decision-making processes in order to boost confidence and enable more fruitful human-AI collaboration [4].

Combining AI and quantum computers for drug development has enormous potential as well. In addition to outperforming conventional computers and enabling more precise predictions of chemical reactions and binding affinities, quantum algorithms offer the potential to replicate molecular interactions with previously unheard-of accuracy. This could revolutionize lead optimization and virtual screening by providing a better understanding of molecular activity [6].

AI will also play a major role in precision and sophisticated tailored medicine. Future AI systems will use a patient's distinct genetic, proteomic, and lifestyle data to forecast individual patient responses, ideal dosage, and possible adverse effects in addition to identifying therapeutic possibilities. Beyond general population-based treatments, this will lead to highly customized medicines that are safer and more successful for specific patients. These forecasts will be significantly improved by the continuous flow of real-world patient data and AI developments [4].

Finally, it is expected that AI will stimulate innovation in the creation of drugs that target "undruggable" targets. Many disease-relevant proteins have not been successfully treated by conventional small molecule or biologic treatments. By employing state-of-the-art computational chemistry techniques and generative designs, future AI models may find whole new chemical scaffolds or therapeutic modalities capable of impacting these challenging targets. This may expand the therapy options for disorders that were thought to be incurable [6].

X. CONCLUSION

The traditional drug development method, which is characterized by lengthy timelines, high failure rates, and exorbitant prices, has historically made it challenging to bring breakthrough medications to patients. However, the introduction of Artificial Intelligence (AI) is significantly altering this complex endeavor at every stage. Through the use of deep learning, natural language processing, generative models, and advanced machine learning, artificial intelligence is revolutionizing target identification, facilitating rapid virtual screening of massive chemical

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

libraries, and deftly customizing lead compounds for desired pharmacological features. AI also speeds up regulatory submissions, boosts the efficacy of preclinical and clinical trials, and enhances post-marketing surveillance for improved drug safety. Even though problems like data quality, interpretability, and regulatory frameworks still exist, the observable benefits of AI—such as significant time and cost savings, enhanced data integration, and the acceleration of personalized medicine—highlight its critical role in the future of pharmaceutical research. AI is not merely a minor advancement, but a fundamental paradigm shift. It naturally speeds up, lowers the cost of, and improves the quality of drug development, which will ultimately expedite the delivery of life-saving medications to those who most need them.

REFERENCES

[1]. Bhumireddy PKS, Kumar BM, Rajasekhar AC, et al. Drug discovery process and emerging modalities: A comprehensive review. J Med Pharm Chem. 2023;5(1):1–13.

[2]. Sai Charan LVKSP, Harish S, Harishankar P, Srikanth PS. Role of artificial intelligence in drug discovery and development. Int J Pharm Sci Rev Res. 2023;80(1):24–9.

[3]. Bawa S. AI in drug discovery: A transformative shift in pharmaceuticals. Int J Res Pharm Sci. 2021;12(3):1774–9.

[4]. Lim JA, Chowdhury AKM, Niyaz TBD, Hossain SM. Artificial intelligence in drug discovery: Promises and challenges. J Adv Pharm Technol Res. 2021;12(1):1–8.

[5]. Islam MT, Akter FJ, Rahman MS. Artificial intelligence in drug discovery: Revolutionizing the pharmaceutical industry. J Pharm Sci Res. 2023;15(1):1–6.

[6]. Kumar SGP, Reddy A, Srikanth R. AI and machine learning in drug discovery and development: Current progress and future directions. Drug Dev Res. 2023;84(1):1–12.

[7]. Khan AR, Hossain MF, Rahman SAJT. Artificial intelligence in drug discovery: A comprehensive review. J Pharm Res Int. 2021;33(1):1–10.

[8]. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–90.

[9]. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038–40.

[10]. Segler MHS, Preuss M, Waller MP. Planning chemical syntheses with deep neural networks and symbolic AI. Nature. 2018;555(7698):604–10.

[11]. Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13

[12]. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97–113.

[13]. Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020; 18:784–90.

[14]. Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and future prospects. Drug Discov Today. 2019;24(3):773–80.

[15]. Gao W, Coley CW. The synthesizability of molecules proposed by generative models. J Chem Inf Model. 2020;60(12):5714–23.

[16]. Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435–41.

[17]. Ragoza M, Hochuli J, Idrobo E, Sunseri J, Koes DR. Protein–ligand scoring with convolutional neural networks. J Chem Inf Model. 2017;57(4):942–57.

[18]. Ghosh S, Nie A, An. J, Huang Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol. 2006;10(3):194–202.

[19]. Walters WP, Murcko M. Assessing the impact of generative AI on medicinal chemistry. Nat Biotechnol. 2020;38(2):143–5.

[20]. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241–50.

[21]. Zeng X, Zhu S, Liu X, et al. deepDR: A network-based deep learning approach to in silico drug repositioning. Bioinformatics. 2019;35(24):5191–8.

[22]. Kadurin A, Nikolenko S, Khrabrov K, Aliper A, Zhavoronkov A. druGAN: An advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico. Mol Pharm. 2017;14(9):3098–104.

[23]. Elton DC, Boukouvalas Z, Fuge MD, Chung PW. Deep learning for molecular design—a review of the state of the art. Mol Syst Des Eng. 2019; 4:828–49.

[24]. Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V. Deep neural nets as a method for quantitative structure–activity relationships. J Chem Inf Model. 2015;55(2):263–74.

[25]. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.

[26]. Recursion Pharmaceuticals. Automated phenotypic screening using AI and image-based profiling [Internet]. Company website.

[27]. Insilico Medicine. AI-powered drug discovery platforms: Chemistry42, PandaOmics [Internet]. Company website.

[28]. BenevolentAI. AI for disease understanding and drug repurposing [Internet]. Company site.

[29]. Atomwise. AI drug discovery using AtomNet deep learning technology [Internet]. Company site.

[30]. DeepChem. Open-source tools for deep learning in drug discovery [Internet]. Project site.

[31]. AiZynthFinder. Open-source software for retrosynthetic planning. J Cheminform. 2020;12(1):70.

[32]. Fang L, Karaman E, Kandoi G, et al. Machine learning models for ADME/Tox properties. Comput Toxicol. 2021; 17:100144.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26apr430

[33]. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning in Drug Development: Discussion Paper. 2021.
[34]. European Medicines Agency. Reflection paper on the use of AI in medicinal product lifecycle. 2023.
[35]. Liang H, Tsui BY, Ni H, et al. Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence. Nat Med. 2019;25(3):433–8.
[36]. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.
[37]. Nature Reviews Drug Discovery. Year-wise progress of AI-discovered drug candidates in clinical trials. 2023.
[38]. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs. Trends Pharmacol Sci. 2016;37(3):118–29.
[39]. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–49.
[40]. Mullard A. AI in drug discovery gains traction. Nat Rev Drug Discov. 2020;19(12):833–6.